canoboi
2021-12-23
Like and comment thks
Allakos rebounds amid bearish views on trial setback
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":698057423,"tweetId":"698057423","gmtCreate":1640268416571,"gmtModify":1640268513740,"author":{"id":3554895157968981,"idStr":"3554895157968981","authorId":3554895157968981,"authorIdStr":"3554895157968981","name":"canoboi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":28,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment thks</p></body></html>","htmlText":"<html><head></head><body><p>Like and comment thks</p></body></html>","text":"Like and comment thks","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/698057423","repostId":1165632180,"repostType":4,"repost":{"id":"1165632180","pubTimestamp":1640268327,"share":"https://www.laohu8.com/m/news/1165632180?lang=&edition=full","pubTime":"2021-12-23 22:05","market":"us","language":"en","title":"Allakos rebounds amid bearish views on trial setback","url":"https://stock-news.laohu8.com/highlight/detail?id=1165632180","media":"seekingalpha","summary":"After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have rec","content":"<p>After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market with arise of ~10.9%on above-average volume. About 4.6M company shares have changed hands compared to the 65-day average volume of ~1.3M.</p>\n<p>According to sites tracking the mentions of ticker symbols on social media sites, Allakos (ALLK) has so far retained its lead as the most popular stock on Twitter in the pre-market.</p>\n<p>The return of investor interest in the mid-cap biotech comes despite its underwhelming data from two late-stage studies for lirentelimab (AK002), an experimental therapy for eosinophilic gastrointestinal diseases (EGID). Both ENIGMA 2 and KRYPTOS trials had not met the patient-reported symptomatic co-primary endpoints with statistical significance, the company said after the close on Tuesday.Amid the selloff, several Wall Street analysts issued bearish views on the stock.</p>\n<p>Double downgrading Allakos (ALLK) to Underperform from Buy, Bank of America argued that the lack of benefit shown in studies “likely spells the end of both programs with little chance of broad approval,” for lirentelimab. The price target cut to $12 from $155 per share implies a premium of ~40.4% to the last close.</p>\n<p>However, Morgan Stanley maintains the Equal Weight rating on the stock despite lowing the price target to $10 from $86 per share, a premium of ~17.0% to the last close. The analysts led by Michael E Ulz argue that despite a significant decline in eosinophils, a co-primary endpoint, there were no benefits seen for symptoms, a key co-primary endpoint for both studies.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos rebounds amid bearish views on trial setback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos rebounds amid bearish views on trial setback\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:05 GMT+8 <a href=https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market with arise of ~10.9%on above-average volume. About 4.6M company shares have...</p>\n\n<a href=\"https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"source_url":"https://seekingalpha.com/news/3782996-alks-stock-rebounds-amid-bearish-views-on-trial-setback","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1165632180","content_text":"After losing more than a quarter of its market cap on Wednesday, Allakos(NASDAQ:ALLK)shares have recovered in the pre-market with arise of ~10.9%on above-average volume. About 4.6M company shares have changed hands compared to the 65-day average volume of ~1.3M.\nAccording to sites tracking the mentions of ticker symbols on social media sites, Allakos (ALLK) has so far retained its lead as the most popular stock on Twitter in the pre-market.\nThe return of investor interest in the mid-cap biotech comes despite its underwhelming data from two late-stage studies for lirentelimab (AK002), an experimental therapy for eosinophilic gastrointestinal diseases (EGID). Both ENIGMA 2 and KRYPTOS trials had not met the patient-reported symptomatic co-primary endpoints with statistical significance, the company said after the close on Tuesday.Amid the selloff, several Wall Street analysts issued bearish views on the stock.\nDouble downgrading Allakos (ALLK) to Underperform from Buy, Bank of America argued that the lack of benefit shown in studies “likely spells the end of both programs with little chance of broad approval,” for lirentelimab. The price target cut to $12 from $155 per share implies a premium of ~40.4% to the last close.\nHowever, Morgan Stanley maintains the Equal Weight rating on the stock despite lowing the price target to $10 from $86 per share, a premium of ~17.0% to the last close. The analysts led by Michael E Ulz argue that despite a significant decline in eosinophils, a co-primary endpoint, there were no benefits seen for symptoms, a key co-primary endpoint for both studies.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1061,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/698057423"}
精彩评论